A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Crizotinib (Primary) ; Dasatinib (Primary)
- Indications Bone metastases; Head and neck cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 28 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 02 Jun 2015 Interim results in 47 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.